No black box warning on record for Xofluza

As of the latest FDA labeling reviewed, Xofluza (BALOXAVIR MARBOXIL) does not carry a black box warning. Standard warnings and precautions still apply — see the full Xofluza medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity such as anaphylaxis, angioedema, urticaria, and erythema multiforme: Initiate appropriate treatment if an allergic-like reaction occurs or is suspected. ( 5.1 ) Increased incidence of Treatment-Emergent Resistance in Patients Less Than 5 Years of Age: XOFLUZA is not indicated in patients less than 5 years of age due to increased incidence of treatment-em

No black box warning on record for Xofluza

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity such as anaphylaxis, angioedema, urticaria, and erythema multiforme: Initiate appropriate treatment if an allergic-like reaction occurs or is suspected. ( 5.1 ) Increased incidence of Treatment-Emergent Resistance in Patients Less Than 5 Years of Age: XOFLUZA is not indicated in patients less than 5 years of age due to increased incidence of treatment-em

Xofluza Black Box Warning

No black box warning on record for Xofluza

Other warnings & precautions

Xofluza Black Box Warning

No black box warning on record for Xofluza

Other warnings & precautions